Long-Acting Formulations of Insulin

2:

• The aqueous pharmaceutical formulation of claim 2, wherein the aqueous pharmaceutical formulation comprises 270-330 U/mL of insulin glargine [equimolar to 270-330 IU human insulin].

3:

• The aqueous pharmaceutical formulation of claim 1, wherein the aqueous pharmaceutical formulation comprises at least one excipient selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20, and sodium.

4:

• The aqueous pharmaceutical formulation of claim 3, wherein the aqueous pharmaceutical formulation comprises 90 μg/mL zinc, 2.7 mg/mL m-cresol, and 20 mg/ml glycerol 85%.

5:

• The aqueous pharmaceutical formulation of claim 3, wherein the aqueous pharmaceutical formulation comprises 90 μg/mL zinc, 2.7 mg/mL m-cresol, 20 μg/mL polysorbate 20, and 20 mg/mL glycerol 85%.

6:

• The aqueous pharmaceutical formulation of claim 1, wherein the pH of the aqueous pharmaceutical formulation is between 3.4 and 4.6.

7:

• The aqueous pharmaceutical formulation of claim 6, wherein the pH of the aqueous pharmaceutical formulation is 4.

8:

• The aqueous pharmaceutical formulation of claim 6, wherein the pH of the aqueous pharmaceutical formulation is 4.5.

9:

• A method of treating Type I and Type II Diabetes Mellitus in a patient in need thereof, comprising administering to the patient an aqueous pharmaceutical composition comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

10:

• The method of claim 9, wherein the aqueous pharmaceutical composition comprises 270-330 U/mL of insulin glargine [equimolar to 270-330 IU human insulin].

11:

• The method of claim 9, wherein the aqueous pharmaceutical composition comprises at least one excipient selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20, and sodium.

12:

• The method of claim 11, wherein the aqueous pharmaceutical composition comprises 90 μg/mL zinc, 2.7 mg/mL m-cresol, and 20 mg/ml glycerol 85%.

13:

• The method of claim 11, wherein the aqueous pharmaceutical composition comprises 90 μg/mL zinc, 2.7 mg/mL m-cresol, 20 μg/mL polysorbate 20, and 20 mg/mL glycerol 85%.

14:

• The method of claim 9, wherein the pH of the aqueous pharmaceutical composition is between 3.4 and 4.6.

15:

• The method of claim 14, wherein the pH of the aqueous pharmaceutical composition is 4.

16:

• The method of claim 14, wherein the pH of the aqueous pharmaceutical composition is 4.5.